Table 1.
Indications | All | ORR | Median PFS | Median OS | ||||
---|---|---|---|---|---|---|---|---|
81 | 74 | 62 | 45 | |||||
Haematological (%) | 20 (25) | 17 (23) | 12 (19) | 7 (16) | ||||
CMA (%) | 22 (27) | 20 (27) | 16 (26) | 8 (18) | ||||
Phase II | Phase III | Phase II | Phase III | Phase II | Phase III | Phase II | Phase III | |
Trials | 136 | 116 | 121 | 105 | 108 | 85 | 66 | 59 |
Randomized (%) | 44 (32) | 116 (100) | 39 (32) | 105 (100) | 34 (31) | 85 (100) | 17 (26) | 59 (100) |
Blinded (%) | 10 (7) | 43 (37) | 8 (7) | 37 (35) | 5 (5) | 28 (33) | 4 (6) | 17 (29) |
Combination (%) | 54 (40) | 53 (46) | 48 (40) | 49 (47) | 41 (38) | 35 (41) | 19 (29) | 18 (31) |
Previous treatment (%) | 93 (68) | 78 (67) | 82 (68) | 70 (67) | 76 (70) | 59 (69) | 45 (68) | 40 (68) |
Mean participants (SD) | 85 (101) | 319 (199) | 86 (105) | 314 (197) | 88 (112) | 319 (187) | 88 (134) | 335 (207) |